Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups. Lambertini M, et al. Among authors: del mastro l. Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10. Eur J Cancer. 2017. PMID: 27951450 Clinical Trial.
Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
Venturini M, Del Mastro L, Melioli G, Balleari E, Garrone O, Pasquetti W, Bason C, Ghio R, Bruzzi P, Rosso R. Venturini M, et al. Among authors: del mastro l. Cancer. 1994 Oct 15;74(8):2300-6. doi: 10.1002/1097-0142(19941015)74:8<2300::aid-cncr2820740814>3.0.co;2-k. Cancer. 1994. PMID: 7522948
Randomized cooperative study of perioperative chemotherapy in breast cancer.
Sertoli MR, Bruzzi P, Pronzato P, Queirolo P, Amoroso D, Del Mastro L, Venturini M, Vigani A, Bertelli G, Campora E, et al. Sertoli MR, et al. Among authors: del mastro l. J Clin Oncol. 1995 Nov;13(11):2712-21. doi: 10.1200/JCO.1995.13.11.2712. J Clin Oncol. 1995. PMID: 7595729 Clinical Trial.
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, Lauria R, Marinelli A, Gallo C. Bianco AR, et al. Among authors: del mastro l. Ann N Y Acad Sci. 1993 Nov 30;698:330-8. doi: 10.1111/j.1749-6632.1993.tb17223.x. Ann N Y Acad Sci. 1993. PMID: 8279772 Clinical Trial. No abstract available.
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR. Venturini M, et al. Among authors: del mastro l. J Clin Oncol. 1996 Mar;14(3):764-73. doi: 10.1200/JCO.1996.14.3.764. J Clin Oncol. 1996. PMID: 8622022 Clinical Trial.
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R. Venturini M, et al. Among authors: del mastro l. Cancer Chemother Pharmacol. 1996;38(6):487-94. doi: 10.1007/s002800050516. Cancer Chemother Pharmacol. 1996. PMID: 8823488
325 results